Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

White Blood Cell And Cell-free DNA Analyses For Detection Of Residual Disease In Gastric Cancer

Alessandro Leal, N. C. V. van Grieken, Doreen N. Palsgrove, J. Phallen, Jamie E. Medina, Carolyn Hruban, M. A. Broeckaert, V. Anagnostou, Vilmos Adleff, Daniel C. Bruhm, J. V. Canzoniero, J. Fiksel, Marianne Nordsmark, Fabienne A. R. M. Warmerdam, H. M. Verheul, D. J. van Spronsen, L. Beerepoot, M. Geenen, J. Portielje, E. Jansen, J. V. van Sandick, E. Meershoek-Klein Kranenbarg, H. V. van Laarhoven, D. L. van der Peet, C. V. D. van de Velde, M. Verheij, R. Fijneman, R. Scharpf, G. Meijer, Annemieke Cats, V. Velculescu
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Liquid biopsies are providing new opportunities for detection of residual disease in cell-free DNA (cfDNA) after surgery but may be confounded through identification of alterations arising from clonal hematopoiesis. Here, we identify circulating tumor-derived DNA (ctDNA) alterations through ultrasensitive targeted sequencing analyses of matched cfDNA and white blood cells from the same patient. We apply this approach to analyze samples from patients in the CRITICS trial, a phase III randomized controlled study of perioperative treatment in patients with operable gastric cancer. After filtering alterations from matched white blood cells, the presence of ctDNA predicts recurrence when analyzed within nine weeks after preoperative treatment and after surgery in patients eligible for multimodal treatment. These analyses provide a facile method for distinguishing ctDNA from other cfDNA alterations and highlight the utility of ctDNA as a predictive biomarker of patient outcome to perioperative cancer therapy and surgical resection in patients with gastric cancer. Identifying patients that will respond to a particular therapy remains a key challenge in precision oncology. Here, in gastric cancer, the authors show that circulating tumour DNA can predict recurrence, provided that the signal from white blood cells is filtered out.
This paper references
10.1158/1538-7445.AM2016-4342
Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium
B. Li (2016)
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
안성민 (2011)
10.1001/jamaoncol.2019.0528
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
T. Reinert (2019)
10.1200/JCO.18.02052
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
E. Christensen (2019)
10.1126/scitranslmed.aan2415
Direct detection of early-stage cancers using circulating tumor DNA
J. Phallen (2017)
10.1101/gr.239244.118
Maftools: efficient and comprehensive analysis of somatic variants in cancer.
A. Mayakonda (2018)
10.1038/nm.3733
Age-related cancer mutations associated with clonal hematopoietic expansion
M. Xie (2014)
10.1056/NEJMOA055531
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
D. Cunningham (2006)
10.1016/S0140-6736(16)30354-3
Gastric cancer
E. Cutsem (2016)
10.1126/scitranslmed.3007094
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
C. Bettegowda (2014)
10.1093/annonc/mdy513
Biological background of the genomic variations of cf-DNA in healthy individuals
J. Liu (2019)
10.1126/scitranslmed.3004742
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
Rebecca J. Leary (2012)
10.1016/j.cell.2018.03.022
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
K. Hoadley (2018)
10.1101/319855
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Markus Mayrhofer (2018)
간담췌 종양에 대한 American Joint Committee on Cancer (AJCC) 종양 병기 7판 소개
유희철 (2010)
10.1158/2159-8290.CD-13-1014
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.
D. Haber (2014)
10.1245/s10434-013-2950-5
Association of Positive Transection Margins with Gastric Cancer Survival and Local Recurrence
K. Bickenbach (2013)
10.1038/s41467-018-07466-6
Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease
J. Moss (2018)
10.1016/S0140-6736(18)32557-1
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
S. Al-Batran (2019)
10.1097/01.sla.0000152019.14741.97
Prediction of Recurrence After Radical Surgery for Gastric Cancer: A Scoring System Obtained From a Prospective Multicenter Study
D. Marrelli (2005)
10.1016/S1470-2045(18)30132-3
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
A. Cats (2018)
an international, open-label, randomised phase 3 trial
Cats (2018)
10.1038/nm.1789
Circulating mutant DNA to assess tumor dynamics
F. Diehl (2008)
10.1200/JCO.2015.33.15_SUPPL.1529
Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation.
V. Anagnostou (2015)
10.1038/nature12065
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
M. Murtaza (2013)
10.1038/nm.3519
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Aaron M. Newman (2014)
diffuse and so-called intestinal-type carcinoma
Lauren (1965)
10.1038/s41586-019-1272-6
Genome-wide cell-free DNA fragmentation in patients with cancer
S. Cristiano (2019)
10.1158/0008-5472.CAN-07-0605
Serial assessment of human tumor burdens in mice by the analysis of circulating DNA.
C. Rago (2007)
10.1158/0008-5472.CAN-18-1082
Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.
J. Phallen (2019)
10.1126/scitranslmed.aab0021
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas (2015)
10.1200/JCO.2015.65.7692
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
E. Smyth (2016)
Surgical treatment of gastric cancer : 15 - year follow - up results of the randomised nationwide Dutch D 1 D 2 trial
I. Songun (2010)
10.1002/cncr.11660
Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
K. Becker (2003)
10.1016/j.cels.2019.05.005
CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers.
C. Tokheim (2019)
a scoring system obtained from a prospective multicenter study
Marrelli (2005)
10.1002/humu.22932
dbNSFP v3.0: A One‐Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice‐Site SNVs
X. Liu (2016)
American Joint Committee on Cancer: AJCC Cancer Staging Manual 6th edn
F L Greene (2002)
10.1002/gcc.20815
Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors
D. J. McBride (2010)
10.1093/annonc/mdv177
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
J. Tie (2015)
10.1093/annonc/mdz046
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
B. Li (2019)
10.1126/scitranslmed.aaf6219
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
J. Tie (2016)
10.1158/1078-0432.CCR-16-1691
The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
S. Parpart-Li (2016)
10.1093/annonc/mdz227
How liquid biopsies can change clinical practice in oncology.
G. Siravegna (2019)
10.1146/annurev-med-062310-094219
Circulating tumor cells and circulating tumor DNA.
C. Alix-Panabières (2012)
10.1158/2159-8290.CD-17-0716
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
Aadel A. Chaudhuri (2017)
10.1111/APM.1965.64.1.31
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.
P. Laurén (1965)
Detection of circulating tumor DNA in early- and latestage human malignancies
C Bettegowda (2014)
10.1016/J.BREASTDIS.2013.10.034
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
N. Tokudome (2013)
10.3390/cancers11030396
Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients
L. Cabel (2019)
10.1016/S1470-2045(10)70070-X
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.
I. Songun (2010)
10.1038/nature13480
Comprehensive molecular characterization of gastric adenocarcinoma
A. Bass (2014)
10.1158/1078-0432.CCR-18-0143
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Y. Hu (2018)
10.3748/wjg.v23.i19.3379
Follow-up after curative resection for gastric cancer: Is it time to tailor it?
P. Aurello (2017)
10.1056/NEJMoa1408617
Age-related clonal hematopoiesis associated with adverse outcomes.
S. Jaiswal (2014)
10.1007/s00428-017-2232-x
Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy
R. Langer (2017)
10.1158/1078-0432.CCR-15-1627-T
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
C. Paweletz (2015)
Is it time to tailor it? World J
Aurello (2017)
10.1007/s00104-017-0458-4
„Liquid biopsy“
K. Hekmat (2017)
10.1016/S1470-2045(14)70028-2
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
T. Conroy (2014)
10.1038/s41571-018-0058-3
Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection
C. Abbosh (2018)
10.1038/s41576-018-0071-5
Current and future perspectives of liquid biopsies in genomics-driven oncology
E. Heitzer (2018)
10.1038/nature22364
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
C. Abbosh (2017)
10.1056/NEJMoa1409405
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.
Giulio Genovese (2014)
10.1038/nature11219
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
L. Diaz (2012)
10.1126/scitranslmed.aax7392
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
B. R. McDonald (2019)
10.1001/jama.2017.12131
Cancer DNA in the Circulation: The Liquid Biopsy.
H. Husain (2017)



This paper is referenced by
10.3390/cancers12030592
Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches
A. Sanjeevaiah (2020)
10.1136/esmoopen-2020-000749
In the literature: April 2020
V. Gambardella (2020)
10.1101/2020.06.27.175471
Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
A. R. Brannon (2020)
10.1016/j.currproblcancer.2020.100685
Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Eo Jin Kim (2020)
10.1159/000510489
Biomarkers for Precision Treatment in Gastric Cancer
A. Petrillo (2020)
10.21203/RS.3.RS-120695/V1
Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assay
A. R. Brannon (2020)
10.1002/ijc.33362
Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer
Xiaoyuan Tian (2020)
10.1158/1055-9965.EPI-20-0549
Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia
J. Cohen (2020)
10.1055/s-0040-1716333
Targeted Sequencing Analysis of Matched Cell-Free DNA and White Blood Cells: A Facile Method for Detection of Residual Disease in Gastric Cancer
Fei-Yu Diao (2020)
10.3390/ijms21249400
Overview of Epstein–Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options
V. Re (2020)
10.1186/s12885-020-07252-y
Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study
S. J. Schraa (2020)
10.3389/fonc.2020.01055
The Metastatic Cascade as the Basis for Liquid Biopsy Development
Zahra Eslami-S (2020)
10.3390/ijms21165832
Controlled Drug Release and Cytotoxicity Studies of Beta-Lapachone and Doxorubicin Loaded into Cyclodextrins Attached to a Polyethyleneimine Matrix
A. Kowalczyk (2020)
10.3390/cancers12082277
Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
Hiu Ting Chan (2020)
10.3389/fonc.2020.614907
Towards Personalization in the Curative Treatment of Gastric Cancer
A. E. Slagter (2020)
10.1016/j.ijrobp.2020.05.008
The Utility of Liquid Biopsies in Radiation Oncology.
Steven De Michino (2020)
Semantic Scholar Logo Some data provided by SemanticScholar